Mirum Pharma CMO reports 55-share holding

Mirum Pharmaceuticals, Inc. (MIRM) lists Chief Medical Officer Robert Paul Myers as directly holding 55 shares of common stock in an ownership entry dated September 21, 2026.

Available on EDGAR 09/22/2026 - 09:51 PM EDT Accepted by SEC EDGAR 09/22/2026 - 09:50 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. (MIRM) lists Chief Medical Officer Robert Paul Myers as directly holding 55 shares of common stock in an ownership entry dated September 21, 2026. The entry reports a holding rather than a stated purchase or sale.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Myers Robert Paul

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Holding	Common Stock	--	--	--

Holdings: Common Stock — 55 shares (Direct)

Key Figures

Direct common-stock holding: 55 shares

1 metrics

Direct common-stock holding 55 shares Entry dated September 21, 2026

Key Terms

Common Stock, direct ownership

2 terms

Common Stock financial

"55 shares of Common Stock held directly"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

direct ownership financial

"55 shares held directly"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MIRM shares did Chief Medical Officer Robert Paul Myers report holding?

Robert Paul Myers reported a direct holding of 55 shares of Mirum Pharmaceuticals common stock.

When was the MIRM ownership entry for Robert Paul Myers dated?

The ownership entry is dated September 21, 2026.

Was Robert Paul Myers's MIRM entry a purchase or a sale?

It is reported as a direct holding entry rather than a stated purchase or sale.

What role does Robert Paul Myers hold at Mirum Pharmaceuticals?

Robert Paul Myers is identified as Mirum Pharmaceuticals' Chief Medical Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Myers Robert Paul

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E. HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/21/2026

3. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	55	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Rob Myers	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)